Organon & Co. (OGN): Modelo de negócios Canvas [Jan-2025 Atualizado]

Na paisagem dinâmica da inovação farmacêutica, Organon & A Co. (OGN) surge como uma força transformadora, posicionando-se estrategicamente na interseção dos cuidados de saúde e soluções médicas de ponta. Ao criar meticulosamente um modelo de negócios abrangente que abrange pesquisa inovadora, desenvolvimento direcionado de produtos e envolvimento global do mercado, a Organon se distinguiu como uma empresa pioneira comprometida em avançar a saúde das mulheres por meio de sofisticadas intervenções farmacêuticas. Essa exploração de seu modelo de negócios Canvas revela as intrincadas estratégias que impulsionam sua missão, oferecendo um vislumbre convincente de como uma empresa moderna de saúde navega com dinâmica complexa de mercado, mantendo um foco inabalável na inovação centrada no paciente.

Organon & Co. (OGN) - Modelo de Negócios: Principais Parcerias

Colaboração estratégica com fabricantes farmacêuticos

A Organon estabeleceu parcerias estratégicas com vários fabricantes farmacêuticos para aprimorar seu portfólio de produtos e recursos de fabricação.

Parceiro	Foco de colaboração	Ano estabelecido
Merck & Co.	Fabricação de produtos para saúde feminina	2021
Bayer AG	Desenvolvimento biossimilar	2022

Parcerias de pesquisa com instituições acadêmicas globais

Organon mantém relações de pesquisa colaborativa com os principais centros de pesquisa acadêmica.

• Faculdade de Medicina de Harvard - Pesquisa em Saúde da Mulher
• Universidade Johns Hopkins - Desenvolvimento de Tecnologia Biossimilar
• Universidade de Stanford - Inovação da Saúde Reprodutiva

Acordos de distribuição com prestadores de serviços de saúde

A Organon estabeleceu redes abrangentes de distribuição em vários sistemas de saúde.

Prestador de cuidados de saúde	Cobertura geográfica	Categorias de produtos
CVS Health	Estados Unidos	Saúde da Mulher, Biossimilares
Kaiser Permanente	América do Norte	Produtos contraceptivos

Acordos de licenciamento para tecnologias farmacêuticas

A Organon garantiu vários acordos de licenciamento de tecnologia para expandir suas capacidades farmacêuticas.

• Contrato de licenciamento com Fujifilm Kyowa Kirin Biologics - Tecnologias biossimilares
• Contrato de transferência de tecnologia com Moderna - Plataformas de pesquisa de mRNA

Joint ventures na saúde da mulher e desenvolvimento biossimilar

Organon se envolveu em joint ventures estratégicos para acelerar a inovação e a expansão do mercado.

Parceiro de joint venture	Área de foco	Valor do investimento
Pfizer Inc.	Tecnologias de Saúde Reprodutiva das Mulheres	US $ 75 milhões
Novartis AG	Desenvolvimento clínico biossimilar	US $ 120 milhões

Organon & Co. (OGN) - Modelo de negócios: Atividades -chave

Pesquisa e desenvolvimento de produtos farmacêuticos

Em 2023, Organon & A Co. investiu US $ 502 milhões em atividades de pesquisa e desenvolvimento. A empresa se concentrou no desenvolvimento de terapias inovadoras em várias áreas terapêuticas.

Investimento em P&D	Áreas terapêuticas	Número de projetos de pesquisa ativos
US $ 502 milhões (2023)	Saúde das mulheres	12 projetos de pesquisa ativos
8,7% da receita total	Biossimilares	5 programas de estágio clínico

Fabricação de medicamentos prescritos

A Organon opera instalações de fabricação em vários locais globais.

• Sites de fabricação totais: 7 instalações globais
• Capacidade anual de produção: 1,2 bilhão de unidades de produtos farmacêuticos
• Locais de fabricação: Estados Unidos, Irlanda, China, Brasil

Comercialização do portfólio de saúde da mulher

Categoria de produto	Receita (2023)	Quota de mercado
Produtos contraceptivos	US $ 1,2 bilhão	18.5%
Terapia hormonal	US $ 675 milhões	12.3%

Ensaios clínicos e desenvolvimento de medicamentos

Em 2023, o Organon conduziu 18 ensaios clínicos ativos em vários estágios de desenvolvimento.

• Ensaios de Fase I: 4 estudos ativos
• Ensaios de Fase II: 8 estudos ativos
• Ensaios de Fase III: 6 estudos ativos

Conformidade regulatória e registro de produtos

Organon manteve a conformidade regulatória em várias jurisdições.

Aprovações regulatórias (2023)	Número de aprovações	Órgãos regulatórios
Novas aplicações de drogas	3 aprovações	FDA, Ema
Extensões da linha de produtos	5 aprovações	Agências regulatórias globais

Organon & Co. (OGN) - Modelo de negócios: Recursos -chave

Extensa infraestrutura de pesquisa farmacêutica

Orçamento de pesquisa e desenvolvimento: US $ 845 milhões em 2023

Locais das instalações de pesquisa	Número de centros de pesquisa
Estados Unidos	3
Europa	2

Talento especializado em experiência em saúde da mulher

Total de funcionários: 9.800 em dezembro de 2023

• Equipe de Pesquisa em Saúde da Mulher: 412 Profissionais Especializados
• Especialistas em pesquisa global: 276 especialistas internacionais

Portfólio de propriedade intelectual

Categoria de patentes	Número de patentes ativas
Saúde das mulheres	87
Biossimilares	42

Instalações de fabricação avançadas

Sites de fabricação totais: 6 locais globais

Local de fabricação	Capacidade de produção anual
Estados Unidos	1,2 bilhão de unidades
Irlanda	890 milhões de unidades

Fortes capital financeiro e capacidades de investimento

Métricas financeiras para 2023:

• Receita total: US $ 6,2 bilhões
• Lucro líquido: US $ 987 milhões
• Porcentagem de investimento em pesquisa: 13,6% da receita total

Organon & Co. (OGN) - Modelo de negócios: proposições de valor

Portfólio abrangente de produtos de saúde feminina

Organon & Co. gera US $ 6,7 bilhões em receita anual, com Produtos de saúde femininos representando 36% do portfólio total. Os principais segmentos de produtos incluem:

Categoria de produto	Receita anual	Quota de mercado
Contraceptivos	US $ 1,2 bilhão	18.5%
Tratamentos de fertilidade	US $ 850 milhões	14.3%
Terapias hormonais	US $ 670 milhões	11.2%

Soluções farmacêuticas inovadoras

O investimento em P&D totaliza US $ 624 milhões anualmente, com foco em áreas terapêuticas especializadas.

• 5 programas de desenvolvimento farmacêutico ativos
• 12 Formulações farmacêuticas protegidas por patentes
• 3 intervenções terapêuticas inovadoras em ensaios clínicos

Intervenções de saúde focadas no paciente

Organon serve 68 países com soluções de saúde direcionadas. As estratégias de intervenção do paciente incluem:

Tipo de intervenção	Alcance do paciente	Investimento anual
Programas de saúde digital	1,2 milhão de pacientes	US $ 92 milhões
Serviços de apoio ao paciente	875.000 pacientes	US $ 53 milhões

Medicamentos prescritos de alta qualidade

O portfólio de medicamentos prescritos abrange:

• 47 produtos farmacêuticos aprovados pela FDA
• 22 categorias terapêuticas
• US $ 3,4 bilhões em receita de medicamentos prescritos

Tratamentos terapêuticos acessíveis e direcionados

Métricas de acessibilidade ao tratamento:

Categoria de tratamento	Disponibilidade global	Cobertura do paciente
Saúde reprodutiva	52 países	3,6 milhões de pacientes
Tratamentos de neurociência	41 países	2,1 milhões de pacientes
Intervenções cardiovasculares	38 países	1,9 milhão de pacientes

Organon & Co. (OGN) - Modelo de Negócios: Relacionamentos do Cliente

Engajamento profissional médico direto

Organon & Co. mantém o envolvimento direto com os profissionais médicos por meio de:

Canal de engajamento	Volume anual de interação
Interações representativas de vendas	Aproximadamente 3.200 contatos profissionais médicos diretos por trimestre
Apresentações da conferência médica	42 conferências médicas em 2023
Webinars médicos profissionais	28 seminários on -line especializados anualmente

Programas de apoio ao paciente e educação

As iniciativas de apoio ao paciente incluem:

• Programas dedicados de assistência ao paciente para 7 áreas terapêuticas
• Programas de apoio financeiro que cobrem os custos de medicação
• Recursos de educação digital do paciente

Métrica do programa	2023 dados
Inscrição do programa de apoio ao paciente	124.567 pacientes
Assistência financeira fornecida	US $ 42,3 milhões em apoio ao paciente

Plataformas e recursos de saúde digital

Estratégias de engajamento em saúde digital:

• Aplicativo de saúde móvel
• Portais de pacientes online
• Plataformas de consulta de telessaúde

Métrica da plataforma digital	2023 Estatísticas
Downloads de aplicativos móveis	287.456 Downloads
Usuários ativos do portal online	163.892 usuários registrados

Serviços personalizados de consulta de saúde

Abordagem personalizada de consulta de saúde:

• Consultas médicas individuais
• Programas especializados de gerenciamento de doenças
• Orientação da via de tratamento personalizada

Serviço de consulta	2023 desempenho
Consultas individuais	45.678 consultas personalizadas
Participantes do Programa de Gerenciamento de Doenças	92.345 pacientes inscritos

Canais de comunicação médica contínua

Infraestrutura de comunicação:

• Helpline de informações médicas 24/7
• Sistemas de suporte por e -mail
• Portais de informações médicas dedicadas

Canal de comunicação	Desempenho anual
Chamadas de linha de linha médica	76.543 chamadas de suporte
Interações por e -mail de suporte	98.765 Comunicações por e -mail

Organon & Co. (OGN) - Modelo de Negócios: Canais

Força de vendas direta para profissionais de saúde

A partir do quarto trimestre 2023, Organon & A Co. mantém uma força de vendas direta de 1.247 representantes profissionais direcionados aos prestadores de serviços de saúde em várias áreas terapêuticas.

Métrica do canal de vendas	2023 dados
Total de representantes de vendas	1,247
Cobertura média do território	87 Instalações de saúde por representante
Interações anuais de engajamento de vendas	342.156 Interações médicas

Plataformas de informações médicas online

Organon opera plataformas digitais com as seguintes características:

• 3 Portais de informações de saúde digital proprietárias
• Usuários ativos mensais: 156.720
• Engajamento anual de conteúdo digital: 2,4 milhões de interações profissionais de saúde

Redes de distribuição farmacêutica

Métricas de rede de distribuição para 2023:

Canal de distribuição	Cobertura
Distribuidores por atacado	47 países
Parcerias diretas do hospital	1.836 instituições de saúde
Alcance da rede de farmácias	62.400 farmácias globalmente

Conferência Médica e Participação do Simpósio

Estatísticas de envolvimento da conferência para 2023:

• Total de conferências participadas: 124
• Apresentações científicas entregues: 87
• Total de participantes profissionais envolvidos: 34.562

Comunicação de marketing digital e saúde

Métricas de comunicação digital para 2023:

Canal digital	Métricas de engajamento
Plataformas profissionais de mídia social profissional de saúde	92.340 seguidores
Participação de on -line	26 webinars, 14.780 profissionais registrados
Campanhas de marketing por email	1,2 milhão de e -mails profissionais de saúde direcionados

Organon & Co. (OGN) - Modelo de negócios: segmentos de clientes

Ginecologistas e especialistas em saúde da mulher

Tamanho do segmento de clientes: aproximadamente 54.000 ginecologistas praticantes nos Estados Unidos a partir de 2023.

Foco especial	Número de especialistas	Penetração de mercado
Saúde reprodutiva	22,500	42%
Tratamentos de fertilidade	8,750	16%

Instituições de Saúde

Mercado endereçável total: 6.090 hospitais nos Estados Unidos em 2023.

• Centros Médicos Acadêmicos: 141
• Hospitais comunitários: 4.500
• Clínicas especializadas em saúde das mulheres: 1.449

Redes hospitalares

Cobertura do mercado: 72% das redes hospitalares dos EUA que compram produtos de saúde feminina.

Tipo de rede	Número de redes	Valor anual de compras
Grandes sistemas hospitalares	327	US $ 1,2 bilhão
Redes regionais de saúde	892	US $ 650 milhões

Pacientes individuais

Demografia alvo de pacientes: 83,1 milhões de mulheres de 15 a 49 anos nos Estados Unidos.

• Pacientes de saúde reprodutiva: 42,6 milhões
• Buscadores de tratamento de fertilidade: 7,3 milhões
• Usuários de contracepção: 38,2 milhões

Mercados globais de saúde

Alcance do mercado internacional: 45 países com distribuição ativa de produtos de saúde para mulheres.

Região	Tamanho de mercado	Taxa de crescimento
América do Norte	US $ 12,4 bilhões	4.7%
Europa	US $ 9,6 bilhões	3.9%
Ásia-Pacífico	US $ 7,2 bilhões	5.3%

Organon & Co. (OGN) - Modelo de negócios: estrutura de custos

Investimento significativo em P&D

Em 2023, Organon & A Co. reportou despesas de P&D de US $ 330,2 milhões, representando 7,4% da receita total.

Ano	Despesas de P&D	Porcentagem de receita
2023	US $ 330,2 milhões	7.4%

Despesas de fabricação e produção

Os custos totais de fabricação para o Organon em 2023 foram de US $ 1,2 bilhão, com os principais locais de produção localizados em:

• Estados Unidos
• Irlanda
• China

Local de fabricação	Custos de produção estimados
Estados Unidos	US $ 480 milhões
Irlanda	US $ 350 milhões
China	US $ 370 milhões

Despesas de vendas e marketing

As despesas de vendas e marketing da Organon em 2023 totalizaram US $ 862,5 milhões.

Canal de vendas	Gastos com marketing
Vendas farmacêuticas	US $ 512,3 milhões
Saúde das mulheres	US $ 350,2 milhões

Custos de conformidade regulatória

As despesas de conformidade regulatória em 2023 foram de aproximadamente US $ 175,6 milhões.

Ensaios clínicos e financiamento de pesquisa

Os investimentos em ensaios clínicos para 2023 atingiram US $ 245,8 milhões em várias áreas terapêuticas.

Área terapêutica	Investimento de ensaios clínicos
Saúde das mulheres	US $ 98,3 milhões
Biossimilares	US $ 75,5 milhões
Medicamentos estabelecidos	US $ 72,0 milhões

Organon & Co. (OGN) - Modelo de negócios: fluxos de receita

Vendas farmacêuticas de produtos

No quarto trimestre 2023, a Organon reportou vendas líquidas totais de US $ 1,6 bilhão. O portfólio de produtos farmacêuticos da empresa gerou fluxos de receita específicos:

Categoria de produto	Receita anual (2023)
Produtos de Saúde Feminina	US $ 796 milhões
Marcas estabelecidas	US $ 637 milhões
Biossimilares	US $ 167 milhões

Licenciamento de medicamentos prescritos

Organon gera receita por meio de acordos de licenciamento estratégico com os principais parceiros farmacêuticos.

• Receita de licenciamento para neurociência e medicamentos cardiovasculares
• Royalties de propriedade intelectual de parcerias farmacêuticas globais
• Acordos de desenvolvimento colaborativo gerando pagamentos marcos

Portfólio de produtos de saúde feminina

Receita do segmento de saúde da mulher Receita para 2023:

Produto	Vendas anuais
Nexplanon	US $ 427 milhões
Nuvaring	US $ 233 milhões

Comercialização de produtos biossimilares

Desempenho do segmento biossimilar em 2023:

• Vendas totais de produtos biossimilares: US $ 167 milhões
• Receita biossimilar de renflexis: US $ 84 milhões
• Receita biossimilar de Hadlima: US $ 53 milhões

Receitas de expansão do mercado global

Distribuição de receita geográfica para 2023:

Região	Contribuição da receita
Estados Unidos	US $ 1,2 bilhão
Europa	US $ 286 milhões
Mercados internacionais	US $ 112 milhões

Organon & Co. (OGN) - Canvas Business Model: Value Propositions

You're looking at the core value Organon & Co. delivers across its portfolio as of late 2025. It's a mix of maintaining legacy strength while pushing growth in targeted areas like women's health and complex generics.

The company's overall financial context for 2025 shows a revised full-year revenue guidance in the range of $6.200 billion to $6.250 billion. This is the backdrop against which these value propositions are being delivered.

Improving women's health outcomes across the lifespan (primary mission)

Organon & Co. focuses its primary mission on women's health, which is a strategic pillar. For the three months ended September 30, 2025, the Women's Health segment generated $429 million in revenue, representing a 3% decline as-reported compared to the third quarter of 2024, and a 4% decline excluding foreign exchange impacts (ex-FX). This segment includes key offerings like Nexplanon and fertility treatments.

The fertility business, for instance, showed significant momentum in the first half of 2025. For the three months ended June 30, 2025, the fertility business grew 15% ex-FX, driven partly by a favorable comparison related to an agreement exit in the U.S. from 2023.

Providing cost-effective, high-quality biosimilars (e.g., Hadlima) to health systems

The Biosimilars portfolio is a clear growth engine, offering alternatives to high-cost biologics. In the third quarter of 2025, Biosimilars revenue jumped 19% on both an as-reported basis and ex-FX compared to the prior year period. This strong performance was primarily fueled by Hadlima (adalimumab-bwwd).

To give you a sense of the ramp-up, Hadlima launched in the U.S. in July 2023. The segment's growth in Q3 2025 also benefited from the favorable timing of an international tender for Ontruzant (trastuzumab-dttb). The portfolio also gained new assets in 2025, including the acquisition of Tofidence (tocilizumab-bavi) in the second quarter and the FDA approval of Bilprevda (denosumab-nxxp) in September 2025.

Offering a stable supply of essential, established medicines globally

The Established Brands segment provides the reliable, foundational revenue stream, though it faces structural headwinds from generic competition. For the third quarter of 2025, this segment brought in $956 million, which was a 1% increase as-reported but a 3% decline ex-FX. This segment is the largest contributor to the top line.

The value here is stability and global reach for necessary therapies. However, the ex-FX decline reflects ongoing challenges, such as the loss of exclusivity (LOE) for Atozet (ezetimibe and atorvastatin) in key European markets.

Delivering long-acting reversible contraceptives (LARCs) like Nexplanon

Organon & Co. continues to rely on Nexplanon (etonogestrel implant) as a cornerstone LARC. However, performance has been mixed across geographies in 2025. In the third quarter of 2025, Nexplanon sales decreased 9% ex-FX due to lower demand in the United States, which management linked to decreased funding of government programs. This was partially offset by increased demand in Brazil and tender timing in Mexico.

Still, international performance shows strength; outside the U.S., Nexplanon grew 10% ex-FX in the second quarter of 2025. Management's full-year 2025 expectation is for U.S. sales to be down mid- to high single digits, while international sales are projected to grow mid- to high single digits ex-FX.

Here are the recent Women's Health segment revenue figures:

Metric	Q3 2025 Revenue ($ millions)	Q3 2024 Revenue ($ millions)	YoY Change (ex-FX)
Women's Health Total	429	440	(4)%
Nexplanon (part of WH)	N/A	N/A	(9)% in Q3 2025 ex-FX
NuvaRing (part of WH)	N/A	N/A	5% growth in Q3 2025 ex-FX

Addressing unmet needs in areas like endometriosis and postpartum hemorrhage

While specific revenue for endometriosis or postpartum hemorrhage (PPH) treatments isn't broken out, the focus on future growth drivers points to addressing unmet needs. The company is actively investing in this pipeline, evidenced by the performance of newer assets.

For example, Vtama (tapinarof), a growth driver for dermatological conditions, is on track to achieve a revenue target of $150 million for the full year 2025. Furthermore, the Jada system, which addresses PPH, saw a 29% ex-FX increase in Q3 2025, though the company plans to divest this asset for $440 million plus a $25 million contingency, using proceeds for debt reduction.

The value proposition here is Organon & Co.'s commitment to pipeline development and strategic acquisitions to fill gaps, even while managing the capital structure.

• Vtama is expected to hit $150 million in 2025 revenue.
• The company expects to generate over $900 million of free cash flow before one-time costs in 2025.
• As of September 30, 2025, debt stood at $8.83 billion.

Finance: draft 13-week cash view by Friday.

Organon & Co. (OGN) - Canvas Business Model: Customer Relationships

You're managing relationships with thousands of prescribers and payers across more than 140 markets, so the scale of Organon & Co.'s commercial engine is massive. The investment in direct engagement reflects this global footprint, which supports a portfolio of over 70 medicines and products.

Dedicated direct sales force for physician engagement and education

The dedicated direct sales force is funded through the Selling, General, and Administrative (SG&A) expenses, which represent the direct cost of keeping the commercial engine running. For the fiscal quarter ending in September of 2025, Organon & Co. reported $399 million in Selling and Administration Expenses. This investment supports the field force tasked with physician engagement and education across key therapeutic areas like Women's Health and General Medicines.

Omnichannel engagement strategy for targeted Healthcare Professional (HCP) outreach

Organon & Co. employs a global team of experienced marketers, pricing and access professionals, and data scientists to execute customer engagement strategies optimized across preferred channels aimed at HCPs, patients, and payors. The company's focus on omnichannel engagement is strategic, aiming for seamless, consistent communication across digital and in-person touchpoints. While specific 2025 HCP interaction metrics aren't public, the overall commercial investment is reflected in the company's financial performance, with full-year 2025 revenue guidance affirmed in the range of $6.200 billion to $6.250 billion as of the third quarter of 2025.

Patient support and adherence programs, especially for complex biosimilar transitions

Organon & Co. utilizes patient services, such as the Organon Access Program and the Patient Assistance Program, to help address insurance coverage and financial assistance for eligible patients. This is particularly relevant for complex transitions, including those involving their biosimilars portfolio, which generated $196 million in revenue in the third quarter of 2025. To give you a sense of the industry demand for such support, a Guidehouse Q1 2025 survey indicated that 80% of pharmaceutical executives reported copay assistance as the most used Patient Support Program (PSP) they offered.

The company also manages profit-sharing arrangements that impact net revenue recognition, which is a form of financial relationship management with partners. For instance, under the agreement with Samsung Bioepis, gross profits are shared 65% to Samsung Bioepis and 35% to Organon in certain markets in Brazil.

Institutional contracts and rebate programs with Managed Care and government payers

The relationship with Managed Care organizations and government payers is managed through rebate accruals, which are evaluated quarterly. These accruals are amounts owed based on contractual agreements with private sector (Managed Care) and public sector (Medicaid and Medicare Part D) benefit providers after product dispensing. Organon & Co. is actively managing its access objectives, with the CEO noting significant progress on access for VTAMA in the second quarter of 2025. The company expects to generate more than $900 million of free cash flow before one-time costs in 2025, demonstrating the financial impact of these access strategies.

Here is a snapshot of the financial context underpinning these customer relationship efforts as of late 2025:

Metric	Value (Q3 2025 or Latest Guidance)	Context
Q3 2025 Total Revenue	$1.602 billion	Quarterly sales performance
FY 2025 Revenue Guidance Range	$6.200 billion to $6.250 billion	Full-year outlook
Q3 2025 Selling and Administration Expenses	$399 million	Investment in commercial/sales force
Q3 2025 Adjusted EBITDA Margin	32.3%	Operating efficiency supporting commercial spend
FY 2025 Expected Free Cash Flow (before one-time costs)	Over $900 million	Cash generation supporting access initiatives
Potential Future Milestone Payments Remaining (Samsung Bioepis)	$25 million	Contractual obligation/relationship metric as of June 30, 2025

The company's overall financial health, with cash and equivalents at $672 million as of September 30, 2025, provides the foundation for maintaining these complex, high-touch relationships with both physicians and payers.

Organon & Co. (OGN) - Canvas Business Model: Channels

You're looking at how Organon & Co. gets its medicines from the plant to the patient as of late 2025. It's a complex mix, relying on established pharma infrastructure while pushing digital engagement. The company operates in over 140 markets globally, which means its channel strategy must be highly adaptable.

The overall scale of sales moving through these channels is significant, even with recent guidance adjustments. For the third quarter of 2025, total revenue hit $1.602 billion, and the full-year 2025 revenue guidance was set between $6.200 billion and $6.250 billion.

The composition of that revenue gives you a hint about where the channel focus lies:

• Established Brands accounted for $956 million in Q3 2025 revenue.
• Women's Health revenue was $429 million in Q3 2025.
• Biosimilars revenue reached $196 million in Q3 2025.

Global network of pharmaceutical wholesalers and distributors.

This is the backbone for getting products like Established Brands and Biosimilars out to the broader market. While the exact split of revenue flowing through these third-party logistics partners isn't broken out in the latest reports, the sheer volume of sales across 140+ markets necessitates a robust, tiered wholesaler system. The pressure on the Nexplanon channel in the U.S., for example, saw U.S. sales fall by ~50% in Q3 2025, showing how sensitive this part of the channel can be to policy and buyer behavior, even with global Nexplanon sales at $223 million that quarter.

Direct sales to hospitals, clinics, and government health programs.

This channel is critical for securing formulary placement and driving volume for key hospital-administered or specialty-focused products. The Women's Health segment, which includes contraceptives, is highly dependent on access points like clinics and government programs. The company's focus on achieving access objectives for new products like Vtama Cream suggests direct engagement with payers and institutional buyers is a major channel focus. The company is divesting the Jada system for $440 million plus a $25 million contingency, which will simplify some of its direct commercial focus to concentrate on core areas.

Retail and specialty pharmacies for prescription fulfillment.

For prescription fulfillment, the channel relies on the established network of retail pharmacies. This is where patient access to maintenance medications and newer specialty drugs is finalized. The performance of Established Brands, generating $956 million in Q3 2025, is heavily influenced by prescription volume through these retail points.

Digital platforms and medical science liaisons for HCP communication.

Organon & Co. supports its channel execution with a significant commercialization force dedicated to engaging healthcare providers (HCPs). You should know they have approximately 4,000 employees worldwide dedicated to commercialization activities, which explicitly includes digital and omni-channel strategies. This team structure supports the Medical Science Liaisons (MSLs) and sales representatives who communicate data and value propositions directly to prescribers. The leadership structure includes a Chief Digital and Growth Officer, Rachel Stahler, indicating a formal, dedicated channel for digital outreach. The company aims to execute customer engagement strategies optimized across preferred channels.

Here's a quick look at the revenue mix driving these channel activities in Q3 2025:

Revenue Segment	Q3 2025 Revenue (Millions USD)	Year-over-Year Growth (As-Reported)
Established Brands	$956	1%
Women's Health	$429	(3)%
Biosimilars	$196	19%

Finance: draft a 13-week cash flow view by Friday, focusing on inventory levels relative to the revised full-year guidance of $6.200 billion to $6.250 billion.

Organon & Co. (OGN) - Canvas Business Model: Customer Segments

You're looking at the core groups Organon & Co. targets with its portfolio, which spans Women's Health, Biosimilars, and Established Brands. The numbers tell a clear story about where the focus is right now, especially given the recent Q3 2025 performance data.

Women globally seeking contraception, fertility, and maternal health solutions

This is Organon & Co.'s primary growth engine. The global Women's Health Therapeutics market was valued at an estimated $46.69 billion in 2025, with the U.S. segment alone at $14.05 billion in 2025. Organon & Co.'s own Women's Health franchise was a standout performer, growing 12% on an ex-FX basis to $463 million in Q1 2025.

The contraceptive implant, Nexplanon, is a major driver here, putting it on track to exceed $1 billion in revenue for the full year 2025. However, by Q3 2025, global Nexplanon sales were $223 million, showing a decline of 50% in the U.S. due to policy impacts, though it grew 7% internationally. Fertility treatments also contribute significantly; for instance, Follistim AQ posted a 52% increase ex-FX in Q1 2025.

Here's a quick look at the market context for this segment:

Metric	Value (2025 Estimate/Data)	Source Year
Global Women's Health Therapeutics Market Size	$46.69 billion	2025
U.S. Women's Health Therapeutics Market Size	$14.05 billion	2025
Global Contraceptives Market Share (Largest Segment)	35.07%	2024
Organon & Co. Women's Health Revenue (Q1 2025)	$463 million	Q1 2025

Healthcare systems and payers focused on cost savings via biosimilar adoption

Payers are definitely interested in the cost-effectiveness that biosimilars bring, even if Organon & Co. advocates for policies that don't disproportionately target pharmaceuticals for budget savings. The company's biosimilars revenue increased by 5% in Q2 2025. In 2024, this portfolio brought in $662 million, which was about 10% of total revenues.

The potential for savings is real; biosimilars generally show roughly 35 percent savings over originator products when covered under medical benefits. The recent U.S. FDA approval of POHERDY, the first pertuzumab biosimilar in the U.S., is a key event positioning Organon & Co. to expand access in the biologics market. Still, the company's Q3 2025 revenue guidance revision suggests ongoing pressures, which can be linked to market dynamics affecting biosimilar uptake and legacy product erosion.

Physicians (OB/GYNs, Dermatologists, Oncologists) prescribing specialized therapies

Physicians in these specialties are the gatekeepers for Organon & Co.'s specialized treatments. The company's overall portfolio includes over 70 medicines and products across its three main areas. For oncologists, the launch of the new POHERDY biosimilar broadens the options for treating HER2-positive breast cancer.

For OB/GYNs, the performance of Nexplanon is critical, though its U.S. performance has been volatile, declining 50% in Q3 2025 in budget-constrained public segments like Planned Parenthood and federally qualified health centers. Conversely, the fertility business, which supports specialists in that area, saw growth of 15% ex-FX in Q2 2025. The company also announced an FDA approval in March 2025 for a new non-hormonal treatment for vasomotor symptoms of menopause, which will be a new tool for OB/GYNs managing that patient group.

Patients requiring established, chronic-use medicines (e.g., respiratory, cardiovascular)

This group relies on Organon & Co.'s Established Brands franchise. While specific revenue numbers for this segment aren't broken out for 2025 in the same detail as Women's Health, the company maintains this as a stable foundation. The overall company structure relies on this portfolio, alongside Women's Health and Biosimilars, to generate sufficient cash flows.

Geographically, Organon & Co. has a wide reach, with approximately 75% of its total sales generated outside the United States as of Q1 2025. This global presence means these established medicines serve a broad patient base across more than 140 markets. The full-year 2025 revenue guidance, even after a recent downward revision, sits between $6.2 billion and $6.25 billion, reflecting the combined performance across all segments, including these mature brands.

• Established Brands franchise is a stable component of the portfolio.
• Approximately 56 Established Brands are part of the product lineup.
• 75% of total company revenue is generated outside the United States.

Organon & Co. (OGN) - Canvas Business Model: Cost Structure

The cost structure for Organon & Co. is heavily influenced by the costs inherent in manufacturing and distributing its pharmaceutical portfolio, alongside significant investments in future growth and managing a substantial debt load. You need to map these out clearly to understand the operating leverage.

Cost of Goods Sold (COGS) and Gross Margin

Manufacturing and distribution drive a significant portion of the costs. For the third quarter of 2025, Organon & Co.'s non-GAAP Adjusted gross margin stood at 60.3%. This is slightly below the 61.7% reported in the second quarter of 2025. The reported gross margin for Q3 2025 was even lower at 53.5%, impacted by one-time costs related to optimizing the manufacturing and supply network.

Selling, General, and Administrative (SG&A) Expenses

SG&A expenses are a major operating cost. Guidance for the full year 2025 suggested SG&A would be around 25% of revenue, a figure consistent with the end of 2024. This percentage reflects ongoing actions to improve operating cost efficiency, which serve as offsets to investments needed to grow products like Vtama.

Research and Development (R&D) Investment

Investment in R&D is focused strategically on pipeline expansion, particularly in Women's Health and Biosimilars. For the full year 2025, R&D spending was guided to be approximately 7% of revenue, excluding IPR&D (In-Process Research and Development). Non-GAAP R&D expense for the first quarter of 2025 was down 17%, largely due to the timing of clinical study spend.

Financing Costs and Debt Management

The company carries a significant debt burden, which translates directly into high interest expense. As of September 30, 2025, the reported debt stood at $8.83 billion. The estimated full-year 2025 interest expense was projected to be $510 million. For context, interest payments related to debt instruments for the first six months of 2025 totaled $234 million. The company is actively working to reduce this, aiming for a net leverage ratio below 4.0x by the end of 2025.

Restructuring and Savings Initiatives

Organon & Co. implemented restructuring initiatives in early 2025, including an approximate 6% headcount reduction, to streamline operations. These combined cost savings initiatives are expected to yield approximately $200 million of annual savings. However, these efforts are accompanied by restructuring charges; in June 2025, the company announced anticipated restructuring actions and manufacturing separation costs between $325 million to $375 million that would compress margins in 2025.

Here's a quick look at the key cost drivers based on recent data and guidance:

Cost Component	Metric/Period	Amount/Percentage
Non-GAAP Adjusted Gross Margin	Q3 2025	60.3%
SG&A Expense (Guidance)	Full Year 2025 (% of Revenue)	Approx. 25%
R&D Expense (Guidance)	Full Year 2025 (% of Revenue ex-IPR&D)	Approx. 7%
Total Debt (Reported)	As of September 30, 2025	$8.83 billion
Estimated Interest Expense	Full Year 2025	$510 million
Annual Operational Savings	Expected from Restructuring	Approx. $200 million

The cost structure is being actively managed through efficiency drives, but the fixed cost of servicing the debt remains a critical factor you must account for in any valuation model. The focus is clearly on driving operational savings to offset the high cost of goods and financing.

• Restructuring activities initiated in Q1 2025 targeted an enterprise-wide operating model optimization.
• The company expects to generate over $900 million of free cash flow before one-time costs in 2025.
• Reported debt reduction of $345 million occurred during the second quarter of 2025.
• The weighted-average interest rate on total borrowings as of June 30, 2025, was 5.0%.

Finance: draft 13-week cash view by Friday.

Organon & Co. (OGN) - Canvas Business Model: Revenue Streams

Organon & Co. generates revenue primarily through the sale of pharmaceutical products across three main segments: Established Brands, Women's Health, and Biosimilars. The company's financial outlook for the full year 2025 reflects a focus on managing the decline in legacy products while accelerating growth in newer franchises.

The latest full-year 2025 revenue guidance has been revised to a range of $6.200 billion to $6.250 billion. The projected profitability metric for the same period is an Adjusted EBITDA margin expected to be approximately 31.0% for the full year 2025.

The third quarter of 2025 revenue was $1.602 billion as-reported, which represented a 1% increase as-reported but a 1% decline excluding the impact of foreign currency. Here is a look at the revenue contribution by segment for that quarter:

Revenue Segment	Q3 2025 Revenue (in $ millions)	Year-over-Year Change (As-Reported)	Year-over-Year Change (ex-FX)
Established Brands	956	1%	(3)%
Women's Health	429	(3)%	(4)%
Biosimilars	196	19%	19%

Sales of Established Brands remain the largest revenue stream, contributing $956 million in the third quarter of 2025. However, this segment is facing erosion, with sales declining 3% as-reported year-over-year in Q3 2025. The drag on this segment includes lower sales of Singulair®, which declined approximately 40% excluding foreign exchange in Q3 2025 due to lower demand outside the U.S. and price reductions in Japan and China.

The Women's Health franchise is a strategic focus area, though Q3 2025 revenue was $429 million, down 3% as-reported. You should note the performance of key products within this area:

• Nexplanon global sales for Q3 2025 were $223 million. The company reaffirmed the goal to build Nexplanon into a $1 billion franchise.
• U.S. Nexplanon sales for the full year 2025 are now expected to be down mid- to high single digit, while international Nexplanon sales are projected to grow mid- to high single digits excluding foreign exchange.
• Fertility products delivered double-digit growth in Q2 2025.

Biosimilars sales represent a key growth driver, with revenue reaching $196 million in Q3 2025, a strong 19% growth year-over-year. The growth is being fueled by products like Hadlima:

• Hadlima biosimilar sales were up 63% excluding foreign exchange year-to-date as of Q3 2025.
• Hadlima generated almost $100 million in sales as of the end of Q2 2025.

Newer assets are contributing, but some are tracking below initial expectations. Vtama revenue in Q3 2025 was $34 million, bringing year-to-date revenue to $89 million. The full-year 2025 revenue expectation for Vtama has been lowered to $120 million to $130 million, down from the original $150 million target. The company expects to generate more than $900 million in free cash flow before one-time costs in 2025.